Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2014
Filed with the SEC on Feb 2, 2015 and accepted by EDGAR at Feb 2, 2015, 15:05 ET.
Management's discussion and analysis
As filed, 29,096 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Forward Looking Statements
This report contains information that may constitute "forward-looking statements.” Generally, the words "believe," "expect," "intend," “anticipate,” "estimate," "project," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2014, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
General Discussion
We pursue a strategy of focusing primarily on quality control products, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into three divisions across six physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, gas, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. We follow a philosophy of manufacturing a high quality product and providing a high level of on-going service for those products.
Our revenues come from two main sources – products sales and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products and acquisitions. Biological indicator products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products and continuous monitoring systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, which require periodic repair and recalibration or certification of our instrument products and continuous monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products and systems competitively and, where possible, we try to pass along cost increases in order to maintain our margins.
Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however, differences in gross margins between different product lines, and ultimately the mix of sales will continue to impact our overall gross margin.
Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, it may vary with sales levels. Labor costs and amortization of intangible assets drive the substantial majority of general and administrative expense. Research and development expense is predominantly comprised of labor costs and third party consultants.
In October 2014, we completed a business combination (the “ATI Acquisition”) whereby we acquired substantially all the assets (other than cash and accounts receivable) and certain liabilities of ATI Atlas Limited (“ATI”), a distributor of our biological indicator products.
In October 2014, we completed the PCD Acquisition whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of PCD’s business which is focused on the sale of process challenge devices (“PCD’s) which are used for quality control purposes in the field of ethylene oxide sterilization of medical devices.
In April 2014, we completed the BGI Acquisition whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of BGI’s business which is focused on the sale of equipment primarily used for particulate air sampling.
In April 2014, we completed a business combination (the “Amilabo Acquisition”) whereby we acquired all of the common stock of Amilabo SAS (“Amilabo”), a distributor of our biological indicator products.
In November 2013, we completed a business combination (the “TempSys Acquisition”) whereby we acquired all of the common stock of TempSys, Inc. (“TempSys”), a company in the business of providing continuous monitoring systems to regulated industries.
In November 2013, we completed a business combination (the “Amega Acquisition”) whereby we acquired substantially all the assets and certain liabilities of Amega Scientific Corporation’s (“Amega”) business which provides continuous monitoring systems to regulated industries.
In July 2013, we completed a business combination (the “Suretorque Acquisition”) whereby we acquired substantially all of the assets of ST Acquisitions, LLC’s (“ST Acquisitions”) business involving the design, manufacturing, sale and service of its SureTorque line of bottle cap torque testing instrumentation.
General Trends and Outlook
Our strategic objectives include growth both organically and through further acquisitions. During the nine months ended December 31, 2014, we continued to build our infrastructure to prepare for future growth, including the addition of key personnel to our operations, research and development, and finance teams. We also invested in upgrading our information systems and intend to continue doing so.
The markets for our biological indicators remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for biological indicators is growing as more countries focus on verifying the effectiveness of sterilization processes. General economic conditions over the past few years have, at times, hampered the organic growth of our instruments business, due to the discretionary nature of these products. Additionally, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases. Demand for our instruments products and our continuous monitoring systems, however, is still strong and we strive to grow revenues going forward.
We are working on several research and development projects that, if completed, may result in new products for both existing customers and in new markets. We are hopeful that all of our divisions will have new products available for sale in the coming year.
Results of Operations
The following table sets forth, for the periods indicated, condensed consolidated statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed consolidated financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):
| Three Months Ended December 31, 2014 | 2013 | Change | Percent Change | |
|---|---|---|---|---|
| Revenues | $17,830 | $13,116 | $4,714 | 36% |
| Cost of revenues | 6,778 | 5,410 | 1,368 | 25% |
| Gross profit | $11,052 | $7,706 | $3,346 | 43% |
| Gross profit margin | 62% | 59% | --% | |
| Operating expenses | ||||
| Selling | $1,772 | $1,595 | $177 | 11% |
| General and administrative | 4,740 | 2,781 | 1,959 | 70% |
| Research and development | 832 | 524 | 308 | 59% |
| $7,344 | $4,900 | $2,444 | 50% | |
| Operating income | $3,708 | $2,806 | $902 | 32% |
| Net income | 2,403 | 1,746 | 657 | 38% |
| Net profit margin | 13% | 13% | --% |
Page 15
| Nine Months Ended December 31, 2014 | 2013 | Change | Percent Change | |
|---|---|---|---|---|
| Revenues | $52,770 | $37,010 | $15,760 | 43% |
| Cost of revenues | 20,890 | 14,907 | 5,983 | 40% |
| Gross profit | $31,880 | $22,103 | $9,777 | 44% |
| Gross profit margin | 60% | 60% | --% | |
| Operating expenses | ||||
| Selling | $5,177 | $4,097 | $1,080 | 26% |
| General and administrative | 12,581 | 8,003 | 4,578 | 57% |
| Research and development | 2,459 | 1,639 | 820 | 50% |
| $20,217 | $13,739 | $6,478 | 47% | |
| Operating income | $11,663 | $8,364 | $3,299 | 39% |
| Net income | 7,344 | 5,538 | 1,806 | 33% |
| Net profit margin | 14% | 15% | (1)% |
Revenues
The following table summarizes our revenues by source (in thousands, except percent data):
| Three Months Ended December 31, 2014 | 2013 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $6,964 | $5,317 | $1,647 | 31% |
| Instruments | 8,216 | 6,438 | 1,778 | 28% |
| Continuous Monitoring | 2,650 | 1,361 | 1,289 | 95% |
| Total | $17,830 | $13,116 | $4,714 | 36% |
| Nine Months Ended December 31, 2014 | 2013 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $19,822 | $16,181 | $3,641 | 23% |
| Instruments | 24,966 | 19,468 | 5,498 | 28% |
| Continuous Monitoring | 7,982 | 1,361 | 6,621 | 486% |
| Total | $52,770 | $37,010 | $15,760 | 43% |
Three and nine months ended December 31, 2014 versus December 31, 2013
Biological Indicators revenues for the three and nine months ended December 31, 2014 increased as a result of the Amilabo, ATI and PCD Acquisitions and organic growth of seven and nine percent, respectively which was achieved through existing customers, expansion into new markets and price increases.
Instruments revenues for the three months ended December 31, 2014 increased as a result of the BGI Acquisition and organic growth of 10 percent in our existing product lines. Instruments revenues for the nine months ended December 31, 2014 increased as a result of the BGI Acquisition, organic growth of 9% in our existing product lines and the timing of the prior year acquisition of the Sure Torque product line, partially offset by the disposal of the Nusonics product.
Gross Profit
The following summarizes our gross profit by segment (in thousands, except percent data):
| Three Months Ended December 31, 2014 | 2013 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $4,194 | $2,976 | $1,218 | 41% |
| Gross profit margin | 60% | 56% | 4% | |
| Instruments | 5,412 | 4,137 | 1,275 | 31% |
| Gross profit margin | 66% | 64% | 2% | |
| Continuous Monitoring | 1,446 | 593 | 853 | 144% |
| Gross profit margin | 55% | 44% | 11% | |
| Total gross profit | $11,052 | $7,706 | $3,346 | 43% |
| Gross profit margin | 62% | 59% | 3% |
| Nine Months Ended December 31, 2014 | 2013 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $12,029 | $9,019 | $3,010 | 33% |
| Gross profit margin | 61% | 56% | 5% | |
| Instruments | 15,794 | 12,491 | 3,303 | 26% |
| Gross profit margin | 63% | 64% | (1)% | |
| Continuous Monitoring | 4,057 | 593 | 3,464 | 584% |
| Gross profit margin | 51% | 44% | 7% | |
| Total gross profit | $31,880 | $22,103 | $9,777 | 44% |
| Gross profit margin | 60% | 60% | --% |
Three and nine months ended December 31, 2014 versus December 31, 2013
Biological Indicators gross profit margin percentage for the three and nine months ended December 31, 2014 increased as a result of the Amilabo, ATI and PCD Acquisitions, price increases and volume-based efficiencies associated with revenues growth. The nine months ended December 31, 2014 was negatively impacted by the requirement to replace three product batches that had longer than expected incubation times.
Instruments gross profit margin percentage for the three months ended December 31, 2014 increased primarily due to 10 percent organic revenues growth which allowed fixed costs to be spread over a wider revenues base. Instruments gross profit margin percentage for the nine months ended December 31, 2014 decreased as a result of integration activities associated with the BGI Acquisition and a change in our product/service mix, partially offset by the impact of nine percent organic revenues growth and the application of purchase accounting associated with the Suretorque Acquisition in the prior year.
Continuous Monitoring gross profit margin percentage for the nine months ended December 31, 2014 was negatively impacted by integration activities that commenced soon after the acquisitions were completed. These integration activities have been decreasing over the year and are now substantially complete. As a result, we believe that the Continuous Monitoring gross profit margin percentages on a go forward basis will be impacted more by total revenues available to cover fixed costs and product mix as opposed to ongoing integration activities.
Operating Expenses
Operating expenses for the three and nine months ended December 31, 2014 increased as compared to the prior year as follows (in thousands):
| Increase (Decrease) Three Months Ended December 31, 2014 | Nine Months Ended December 31, 2014 | |
|---|---|---|
| Selling | $177 | $1,080 |
| General and administrative | ||
| ERP system upgrade and SOX compliance | 205 | 250 |
| Acquisition costs | (15) | 389 |
| Amortization | 578 | 1,597 |
| Personnel costs | 1,000 | 3,005 |
| Sales tax accrual | 460 | (646) |
| Other, net | (269) | (17) |
| 1,959 | 4,578 | |
| Research and development | 308 | 820 |
| Operating expenses | $2,444 | $6,478 |
Selling
Three and nine months ended December 31, 2014 versus December 31, 2013
Selling expenses for the three months ended December 31, 2014 increased primarily due to the BGI, Amilabo and PCD Acquisitions along with minor fluctuations due to timing of certain expenses.
Selling expenses for the nine months ended December 31, 2014 increased primarily due to the BGI, Amilabo, Amega, TempSys and PCD Acquisitions, along with negligible increases from other product lines. As a percentage of revenues, selling expense decreased to 10 percent as compared to 11 percent in the prior period. The decrease was due primarily to streamlining sales processes associated with acquisitions along with increased revenues associated with Continuous Monitoring resulting from our integration activities.
General and Administrative
Three and nine months ended December 31, 2014 versus December 31, 2013
General and administrative expenses for the three months ended December 31, 2014 increased primarily due increased amortization and personnel costs resulting from the BGI, Amilabo, Amega, TempSys and PCD acquisitions, increased spending on our ERP system upgrade and an additional $460,000 accrual associated with not properly collecting and remitting sales tax in states in which we most likely had established nexus during prior periods.
General and administrative expenses for the nine months ended December 31, 2014 increased primarily due to increased amortization, personnel and acquisition costs resulting from the BGI, Amilabo, Amega, TempSys and PCD acquisitions, partially offset by the recording of a $1,106,000 accrual in the prior year associated with not properly collecting and remitting sales tax in states in which we most likely had established nexus during prior periods.
Research and Development
Three and nine months ended December 31, 2014 versus December 31, 2013
Research and development expenses for the three and nine months ended December 31, 2014 increased as a result of the Amega, TempSys and BGI Acquisitions and standard increases in personnel costs, partially offset by timing of external research and development consulting projects.
Net Income
Other income (expense), net for the nine months ended December 31, 2014 increased primarily as a result of additional interest expense associated with our Credit Facility as well as the gain on disposal of our Nusonics line of business in the prior period. Our income tax rate varies based upon many factors but in general, we anticipate that on a go forward basis, our effective tax rate will approximate our current rate of 35.3%. Otherwise, net income varied with the changes in revenue, gross profit and operating expenses (which includes $3,440,000 of non-cash amortization of intangible assets for the nine months ended December 31, 2014).
Liquidity and Capital Resources
Our sources of liquidity may include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to shareholders, payment of debt obligations, long-term capital equipment expenditures and potential acquisitions. In addition, we are currently implementing a new ERP system which will require a significant use of cash over the next six to nine months.
Working capital is the amount by which current assets exceed current liabilities. We had working capital of $16,629,000 and $16,351,000, respectively, at December 31, 2014 and March 31, 2014. The increase in working capital is primarily due to increases in both accounts receivable and inventories related to organic growth and the acquisitions of BGI, Amilabo and PCD, partially offset by $3,000,000 of required principal payments under the Term Loan being classified as current liabilities.
In February 2012, we entered into the Credit Facility for a $20,000,000 revolving line of credit and up to $1,000,000 of letters of credit. Funds from the Credit Facility may be used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures. Under the Credit Facility, indebtedness bears interest at either: (1) LIBOR, as defined plus an applicable margin, ranging from 1.25% to 2.00%, or (2) the bank’s commercial bank floating rate (“CBFR”), which is the greater of the bank’s prime rate or one month LIBOR + 2.50%, adjusted down, from 1.25% to 0.50%.
In April 2014, the Credit Facility was amended to include a $15,000,000 term loan and to extend the maturity date of the Credit Facility to June 30, 2017. The Term Loan bears interest at LIBOR, as defined, plus 2% and requires 11 quarterly principal payments (the first due date was July 15, 2014) in the amount of $750,000 with the remaining balance of principal and accrued interest due on April 15, 2017. The proceeds from the Term Loan were used to support acquisition financing and to repay amounts outstanding under the Line of Credit.
The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA, as defined, of 2.5 to 1.0, and a minimum fixed charge coverage ratio of 1.35 to 1.0. We were in compliance with these covenants as of September 30, 2014.
As of January 31, 2015, we had $27,250,000 in outstanding indebtedness and unused capacity under our Credit Facility of $5,500,000.
We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.
On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 162,486 shares of common stock under this program from inception through December 31, 2014.
We have been paying regular quarterly dividends since 2003. Dividends per share paid by quarter were as follows:
| Year Ending March 31, 2015 | 2014 | |
|---|---|---|
| First quarter | $0.15 | $0.14 |
| Second quarter | 0.15 | 0.14 |
| Third quarter | 0.16 | 0.15 |
| Fourth quarter | -- | 0.15 |
Page 19
In January 2015, our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on March 16, 2015, to shareholders of record at the close of business on February 27, 2015.
Cash Flows
Our cash flows from operating, investing and financing activities were as follows (in thousands):
| Nine Months Ended December 31, 2014 | 2013 | |
|---|---|---|
| Net cash provided by operating activities | $6,095 | $9,474 |
| Net cash used in investing activities | (21,262) | (22,905) |
| Net cash provided by financing activities | 11,019 | 11,585 |
Net cash provided by operating activities for the nine months ended December 31, 2014 decreased primarily due to increases in accounts receivable and inventories resulting from the BGI, Amilabo, Amega, TempSys and PCD acquisitions and the payment of accrued liabilities and taxes payable, partially offset by decreases in payments of accounts payable and increases in net income and depreciation and amortization.
Net cash used in investing activities for the nine months ended December 31, 2014 resulted primarily from the $10,268,000 BGI and $5,000,000 PCD Acquisitions and the purchase of $2,212,000 of property, plant and equipment. Net cash used in investing activities for the nine months ended December 31, 2013 resulted from the $11,268,000 Amega Acquisition, the $9,769,000 TempSys Acquisition (net of cash acquired), the $1,721,000 Suretorque Acquisition and the purchase of $808,000 of property, plant and equipment, partially offset by the proceeds from the disposal of the NuSonics product line of $661,000.
Net cash provided by financing activities for the nine months ended December 31, 2014 resulted from borrowings under our Credit Facility of $23,000,000 and proceeds from the exercise of stock options of $1,137,000, partially offset by the repayment of debt of $11,500,000 and the payment of dividends of $1,618,000. Net cash used in financing activities for the nine months ended December 31, 2013 resulted from borrowings under our Line of Credit of $18,000,000 and proceeds from the exercise of stock options of $1,067,000, partially offset by the repayment of debt of $6,000,000 and the payment of dividends of $1,467,000.
At December 31, 2014, we had contractual obligations for open purchase orders of approximately $8,500,000 for routine purchases of supplies and inventory, which are payable in less than one year.
Under the terms of the Amega Agreement, we are required to pay contingent consideration if the cumulative revenues for our Continuous Monitoring Division for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $10,000,000 and is based upon a sliding scale of three-year cumulative revenues between $31,625,000 and $43,500,000. Based upon both historical and projected growth rates, we recorded $500,000 of contingent consideration payable which represents our best estimate of the amount that will ultimately be paid. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our Continuous Monitoring Division and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in the third quarter of our year ending March 31, 2017.
Under the terms of the Bios Agreement, we are required to pay contingent consideration if the cumulative revenues related to the acquisition for the three years subsequent to the acquisition exceed $22,127,000. The potential future payment that we could be required to make ranges from $0 to $6,710,000. Based upon historical growth rates, we initially recorded $2,140,000 of contingent consideration payable which represented our best estimate of the amount that would ultimately be paid. Based upon actual results and current run rates, during the year ended March 31, 2014, we revised our estimate of the ultimate contingent liability that would be paid, which resulted in reducing the contingent consideration payable to $1,120,000. Any further changes to the contingent consideration ultimately paid would result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results associated with the Bios Acquisition and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in the first quarter of our year ending March 31, 2016.
Under the terms of the PCD Agreement, we are required to pay contingent consideration if the cumulative revenues for our process challenge device business for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $1,500,000 and is based upon a sliding scale of three-year cumulative revenues between $9,900,000 and $12,600,000. Based upon both historical and projected growth rates, we recorded $300,000 of contingent consideration payable which represents our best estimate of the amount that will ultimately be paid. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our process challenge device business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in three annual installments beginning in the third quarter of our year ending March 31, 2016.
Critical Accounting Estimates
Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed consolidated financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2014 in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”
Controls and procedures
As filed, 2,998 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of December 31, 2014. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at December 31, 2014.
Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 1992.
Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of December 31, 2014. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at December 31, 2014. As allowed, this evaluation excludes the operations of acquired entities during the nine months ended December 31, 2014 due to the timing of the acquisitions. Revenues related to these acquisitions were 5% of total revenues for the nine months ended December 31, 2014.
Changes in Internal Control Over Financial Reporting
There were no significant changes in our internal control over financial reporting that occurred during the nine months ended December 31, 2014, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 1,755 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2014, under the heading “Part I – Item 1A. Risk Factors.” There have been no material changes to those risk factors other than the following:
The contingent consideration from the PCD Acquisition may negatively impact our available cash and results from operations.
As part of the PCD Acquisition, we are required to make a contingent consideration payment if our cumulative PCD revenues for the three years subsequent to the acquisition meet certain levels. The ultimate amount we pay may differ significantly from the liability we recorded at the time of the acquisition. If we are required to pay more than the amount initially recorded, the difference will be recorded as expense in our consolidated statements of income, which could materially impact our results of operations.
We have claims and lawsuits against us that may result in adverse outcomes
We are subject to a variety of claims and lawsuits. Adverse outcomes in some or all of these claims may result in significant monetary damages or injunctive relief that could adversely affect our ability to conduct our business. The litigation and other claims are subject to inherent uncertainties and management’s view of these matters may change in the future. A material adverse impact on our condensed consolidated financial statements could occur for the period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-10-01 to 2014-12-31 | $17.8m | us-gaap:SalesRevenueNet |
| Revenue | 9 months2014-04-01 to 2014-12-31 | $52.8m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2014-10-01 to 2014-12-31 | $6.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2014-04-01 to 2014-12-31 | $20.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-10-01 to 2014-12-31 | $11.1m | us-gaap:GrossProfit |
| Gross profit | 9 months2014-04-01 to 2014-12-31 | $31.9m | us-gaap:GrossProfit |
| Research and development | 3 months2014-10-01 to 2014-12-31 | $832.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2014-04-01 to 2014-12-31 | $2.5m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2014-10-01 to 2014-12-31 | $3.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2014-04-01 to 2014-12-31 | $11.7m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2014-10-01 to 2014-12-31 | $1.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2014-04-01 to 2014-12-31 | $4.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-10-01 to 2014-12-31 | $2.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2014-04-01 to 2014-12-31 | $7.3m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2014-10-01 to 2014-12-31 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2014-04-01 to 2014-12-31 | $2.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-10-01 to 2014-12-31 | $0.68 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2014-04-01 to 2014-12-31 | $2.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2014-10-01 to 2014-12-31 | 3,654,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2014-04-01 to 2014-12-31 | 3,649,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2014-04-01 to 2014-12-31 | $6.2m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Dividends paid | 9 months2014-04-01 to 2014-12-31 | $1.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2014-12-31 | $1.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-12-31 | $29.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2014-12-31 | $116.2m | us-gaap:Assets |
| Current liabilities | At period end2014-12-31 | $12.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2014-12-31 | $44.5m | us-gaap:Liabilities |
| Long-term debt | At period end2014-12-31 | $25.0m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2014-12-31 | $3.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2014-12-31 | $71.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-15-001592. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.